The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (bbb).
Abstract
In 1995 it was reported for the first time that nanoparticles could be used for the delivery of drugs across the blood-brain barrier (BBB) following intravenous injection. In vitro and in vivo experiments show that the underlying mechanism is receptor-mediated endocytosis followed by transcytosis. No opening of the tight junctions was observed. Due to the overcoating of the nanoparticles with polysorbate 80 or poloxamers 188, apolipoproteins A-I and/or E are adsorbed from the blood on to the particle surface after injection. These apolipoproteins mediate the interaction with LDL or scavenger receptors on the BBB followed by the above brain uptake processes. Likewise, covalent attachment of these apolipoproteins or of transferrin, insulin or antibodies against the respective receptors also enables a similar nanoparticle-mediated drug transport across the BBB. From these results it can be concluded that the nanoparticles act as "Trojan Horses" taking advantage of physiological receptor-mediated transport processes across the BBB.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A possible mechanism of such delivery is adsorption of PS80-coated PACA nanoparticles on ApoE and B from the bloodstream upon intravenous injection followed by transcytosis across BBB using the low-density lipoprotein receptors (Kreuter, 2013).”
From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Kreuter, 2013
Citations
Cites
Cordon‐Cardo, C., O’Brien, J. P., Casals, D., Rittmann-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107
Self-citationNanoparticulate systems for brain delivery of drugs
Kreuter, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.015 · Cited by 965
Self-citationApolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801
Self-citationTransport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715
Self-citationDelivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
Self-citationPassage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)
Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., & Aa, I. (1995) · Brain Research · doi:10.1016/0006-8993(95)00023-j · Cited by 538
Self-citationSignificant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
Gulyaev, A. E., Gelperina, S. E., Skidan, I. N., Antropov, A. S., Kivman, G. Y., & Kreuter, J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018983904537 · Cited by 521
Self-citationKreuter, J., Ramge, P., Petrov, V. E., Hamm, S., Gelperina, S. E., Engelhardt, B., Alyautdin, R. N., von Briesen, H., & Begley, D. J. (2003) · Pharmaceutical Research · doi:10.1023/a:1022604120952 · Cited by 469
Self-citationZensi, A., Begley, D., Pontikis, C., Legros, C., Mihoreanu, L., Wagner, S., Büchel, C., von Briesen, H., & Kreuter, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.002 · Cited by 438
Self-citationChemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles
Steiniger, S. C. J., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., Severin, E. S., Uhl, R., Kock, M., Geiger, K. D., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20048 · Cited by 434
Self-citationAlyautdin, R. N., Petrov, V. E., Langer, K., Berthold, A., Kharkevich, D. A., & Kreuter, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012098005098 · Cited by 352
Self-citationImplications of the Blood-Brain Barrier and Its Manipulation
Neuwelt, E. A. (1989) · Springer eBooks · doi:10.1007/978-1-4613-0701-3 · Cited by 316
Michaelis, K., Hoffmann, M. M., Dreis, S., Herbert, E., Alyautdin, R. N., Michaelis, M., Kreuter, J., & Langer, K. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097139 · Cited by 303
Self-citationPetri, B., Bootz, A., Khalansky, A. S., Hekmatara, T., Müller, R. H., Uhl, R., Kreuter, J., & Gelperina, S. E. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.015 · Cited by 299
Self-citationGelperina, S. E., Maksimenko, O., Khalansky, A. S., Vanchugova, L. V., Шипуло, Е. В., Abbasova, K., Berdiev, R. K., Wohlfart, S., Chepurnova, N. E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.09.003 · Cited by 296
Self-citationThe Blood-brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System
Begley, D. J. (1996) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1996.tb07112.x · Cited by 291
Nerurkar, M. M., Burton, P. S., & Borchardt, R. T. (1996) · Pharmaceutical Research · doi:10.1023/a:1016033702220 · Cited by 287
Kreuter, J., Hekmatara, T., Dreis, S., Vogel, T., Gelperina, S. E., & Langer, K. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.12.012 · Cited by 263
Self-citationTargeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB)
Ulbrich, K., Knobloch, T., & Kreuter, J. (2011) · Journal of Drug Targeting · doi:10.3109/10611861003734001 · Cited by 259
Self-citationReversal of multidrug resistance by surfactants
Woodcock, D., Linsenmeyer, M. E., Chojnowski, G. M., Kriegler, A., Nink, V., Webster, L., & Sawyer, W. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.217 · Cited by 233
Alyautdin, R. N., Tezikov, E. B., Ramge, P., Kharkevich, D. A., Begley, D. J., & Kreuter, J. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006836 · Cited by 229
Self-citationBrain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles
Kurakhmaeva, K. B., Djindjikhashvili, I. A., Petrov, V. E., Balabanyan, V. U., Voronina, T. A., Trofimov, S. S., Kreuter, J., Gelperina, S., Begley, D., & Alyautdin, R. N. (2009) · Journal of Drug Targeting · doi:10.1080/10611860903112842 · Cited by 221
Self-citationOlivier, J.-C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., & Couet, W. (1999) · Pharmaceutical Research · doi:10.1023/a:1018947208597 · Cited by 213
Ramge, P., Unger, R. E., Oltrogge, J. B., Zenker, D., Begley, D. J., Kreuter, J., & von Briesen, H. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00078.x · Cited by 197
Self-citationKreuter, J., Petrov, V. E., Kharkevich, D. A., & Alyautdin, R. N. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00061-8 · Cited by 196
Self-citationGelperina, S. E., Khalansky, A. S., Skidan, I. N., Smirnova, Z. S., Bobruskin, A. I., Severin, E. S., Turowski, B., Zanella, F., & Kreuter, J. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(01)00456-8 · Cited by 185
Self-citationInteraction of Poly(butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrierin vivoandin vitro
Alyaudtin, R. N., Reichel, A., Löbenberg, R., Ramge, P., Kreuter, J., & Begley, D. J. (2001) · Journal of drug targeting · doi:10.3109/10611860108997929 · Cited by 166
Self-citationWohlfart, S., Khalansky, A. S., Gelperina, S. E., Maksimenko, O., Bernreuther, C., Glatzel, M., & Kreuter, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019121 · Cited by 162
Self-citationAlyautdin, R. N., Gothier, D., Петров, Kharkevich, D. A., & Kreuter, J. (1995) · European Journal of Pharmaceutics and Biopharmaceutics · Cited by 148
Self-citationFriese, A. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00073-9 · Cited by 139
Functional Protein Delivery into Neurons Using Polymeric Nanoparticles
Hasadsri, L., Kreuter, J., Hattori, H., Iwasaki, T., & George, J. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805956200 · Cited by 129
Self-citationZensi, A., Begley, D. J., Pontikis, C., Legros, C., Mihoreanu, L., Büchel, C., & Kreuter, J. (2010) · Journal of drug targeting · doi:10.3109/1061186x.2010.513712 · Cited by 119
Self-citationAmbruosi, A., Gelperina, S. E., Khalansky, A. S., Tanski, S., Theisen, A., & Kreuter, J. (2006) · Journal of Microencapsulation · doi:10.1080/02652040600788080 · Cited by 106
Self-citationBorchard, G., Audus, K. L., Shi, F., & Kreuter, J. (1994) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(94)90372-7 · Cited by 105
Self-citationKinetics of transport of doxorubicin bound to nanoparticles across the blood–brain barrier
Wohlfart, S., Khalansky, A. S., Gelperina, S. E., Begley, D. J., & Kreuter, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.05.010 · Cited by 102
Self-citationПереверзева, Э. Р., Трещалин, И. Д., Бодягин, Д. А., Максименко, О. О., Langer, K., Dreis, S., Asmussen, B., Kreuter, J., & Gelperina, S. E. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.01.031 · Cited by 77
Self-citationNanoparticulate Transport of Oximes over an In Vitro Blood-Brain Barrier Model
Wagner, S., Kufleitner, J., Zensi, A., Dadparvar, M., Wien, S., Bungert, J., Vogel, T., Worek, F., Kreuter, J., & von Briesen, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014213 · Cited by 69
Self-citationHekmatara, T., Bernreuther, C., Khalansky, A. S., Theisen, A., Weissenberger, J., Matschke, J., Gelperina, S. E., Kreuter, J., & Glatzel, M. (2009) · Clinical Neuropathology · doi:10.5414/npp28153 · Cited by 61
Self-citationJuan, B. S. D., von Briesen, H., Gelperina, S. E., & Kreuter, J. (2006) · Journal of drug targeting · doi:10.1080/10611860600866872 · Cited by 49
Self-citationIntravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats
Переверзева, Э. Р., Трещалин, И. Д., Бодягин, Д. А., Максименко, О. О., Kreuter, J., & Gelperina, S. E. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.01.020 · Cited by 47
Self-citationTreatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles
Wohlfart, S., Khalansky, A. S., Bernreuther, C., Michaelis, M., Cinatl, J. J., Glatzel, M., & Kreuter, J. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.046 · Cited by 47
Self-citationUltrastructure of Brain Endothelium
Brightman, M. (1992) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-76894-1_1 · Cited by 45
Blood-Brain Barrier Disruption in the Treatment of Brain Tumors
Neuwelt, E. A., & Barnett, P. A. (1989) · Springer eBooks · doi:10.1007/978-1-4615-7255-8_4 · Cited by 44
Blood-Brain Barrier Disruption in the Treatment of Brain Tumors
Neuwelt, E. A., & Dahlborg, S. A. (1989) · Springer eBooks · doi:10.1007/978-1-4615-7255-8_5 · Cited by 44
Tahara, K., Kato, Y., Yamamoto, H., Kreuter, J., & Kawashimà, Y. (2010) · Journal of Microencapsulation · doi:10.3109/02652048.2010.522258 · Cited by 25
Self-citationWohlfart, S., Bernreuther, C., Khalansky, A. S., Theisen, A., Weissenberger, J., Gelperina, S. E., Glatzel, M., & Kreuter, J. (2009) · Journal of Nanoneuroscience · doi:10.1166/jns.2009.1003 · Cited by 11
Self-citationNanoparticulate Carriers for Drug Delivery to the Brain
Kreuter, J. (2006) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860949074_0024 · Cited by 11
Self-citation
Flagged first, then by citations
1 of the 50 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Alyautdin R, 1995, Eur J Pharm Biopharm, 41, 44
- Lück M, 1997. Plasmaproteinadsorption als möglicher Schlüsselfaktor für eine kontrollierte Arzneistoffapplikation mit partikulären Trägern. PhD Thesis, Berlin, Freie Universität, pp. 14–24, 137–54
Cited by
Sorted by citations
Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle
Saptarshi, S. R., Duschl, A., & Lopata, A. L. (2013) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-11-26 · Cited by 1,113
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
“Nanoparticles Actively targeted delivery; brain targeting using specific physiological conditions Crossing the BBB [30-31], [33], [36-39], [44], [46], [47], [50]”
BackgroundCancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
Effect of the surface modification, size, and shape on cellular uptake of nanoparticles
Salatin, S., Dizaj, S. M., & Khosroushahi, A. Y. (2015) · Cell Biology International · doi:10.1002/cbin.10459 · Cited by 626
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Self-citation
Metadata
- Authors
- Kreuter, J.
- Affiliations
- Goethe University Frankfurt (DE)
- Corresponding author
- Kreuter, Jörg
- Venue
- Journal of Microencapsulation
- Publisher
- Informa UK Limited
- Published
- 2012-06-07
- Volume
- 30
- Issue
- 1
- Pages
- 49-54
- ISSN
- 0265-2048 (ISSN-L)
- 1464-5246
- OpenAlex
- W2139835982
- Cited by
- 172
- References
- 50
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 10 · 2023: 14 · 2022: 11 · 2021: 11 · 2020: 20 · 2019: 13 · 2018: 10 · 2017: 10 · 2016: 23 · 2015: 20 · 2014: 7 · 2013: 7 · 2012: 2
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Microencapsulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- blood-brain barrier, polymeric nanoparticles, nanoparticle drug delivery, receptor-mediated endocytosis, transcytosis, tight junctions, apolipoprotein A-I, apolipoprotein E, LDL receptor, scavenger receptors, transferrin, insulin, poloxamer 188, Tween 80, Trojan horse
- MeSH terms
- Animals, Blood-Brain Barrier, Doxorubicin, Polymers, Nerve Growth Factor, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
